A practical reference on albumin conjugate: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
N1-Methyl-2-pyridone-5-carboxamide (also known as 1-methyl-6-oxopyridine-3-carboxamide or nudifloramide and abbreviated as 2PY, 2-Py or NMPC) is one of a number of metabolic products of nicotinamide adenine dinucleotide (NAD) degradation. The presence of 2PY in human blood serum can be an indication of poor kidney performance or chronic kidney disease. 2PY has been identified as a product of the metabolism of caffeine and niacin. 2PY's molecular formula is C7H8N2O2 and its molecular weight 152.153 g/mol.
==== Psychotherapy ==== Psychotherapy for individuals with AN is challenging as they may value being thin and may seek to maintain control and resist change. Initially, developing a desire to change is fundamental. There is no strong evidence to suggest one type of psychotherapy over another for treating anorexia nervosa in adults or adolescents.
Southern Association, previously Class A1 (1936–1945) Texas League, previously Class A1 (1936–1942; idle for three seasons during World War II) The Texas League remained in Double-A for the next 75 years. During this time, there were limited changes to leagues at the Double-A level:
=== Phrixotoxin-1 === Mice that are injected with phrixotoxin-1 can experience numerous, transient, adverse cardiac reactions, such as premature ventricular beats, ventricular tachycardia, and atrio-ventricular blocks. Neurological effects observed are motor impairment and convulsions. These effects are seen following both intravenous and intracisternal injection, making it likely that phrixotoxin-1 crosses the blood brain barrier (Diochot 1999).
It was generally felt in the court that the emperor should marry and produce heirs as soon as possible. Various potential brides were considered, including Archduchess Elisabeth Franziska of Austria, Princess Anna of Prussia and Princess Sidonia of Saxony. Although in public life Franz Joseph was the unquestioned director of affairs, in his private life his mother still wielded crucial influence. Sophie wanted to strengthen the relationship between the Houses of Habsburg and Wittelsbach—descending from the latter house herself—and hoped to match Franz Joseph with her sister Ludovika's eldest daughter, Helene ("Néné"), who was four years the emperor's junior. However, Franz Joseph fell deeply in love with Néné's younger sister Elisabeth ("Sisi"), a beautiful girl of 15, and insisted on marrying her instead. Sophie acquiesced, despite her misgivings about Sisi's appropriateness as an imperial consort, and the young couple were married on 24 April 1854 in St. Augustine's Church, Vienna.
Sources: en.wikipedia.org
==== MeSH D12.776.860.300.250 – collagen ==== MeSH D12.776.860.300.250.300 – fibrillar collagens MeSH D12.776.860.300.250.300.100 – Type I collagen MeSH D12.776.860.300.250.300.200 – Type II collagen MeSH D12.776.860.300.250.300.300 – Type III collagen MeSH D12.776.860.300.250.300.400 – Type V collagen MeSH D12.776.860.300.250.300.500 – Type XI collagen MeSH D12.776.860.300.250.400 – non-fibrillar collagens MeSH D12.776.860.300.250.400.100 – Type IV collagen MeSH D12.776.860.300.250.400.200 – Type VI collagen MeSH D12.776.860.300.250.400.300 – Type VII collagen MeSH D12.776.860.300.250.400.400 – Type VIII collagen MeSH D12.776.860.300.250.400.500 – Type X collagen MeSH D12.776.860.300.250.400.525 – Type XIII collagen MeSH D12.776.860.300.250.400.537 – Type XVIII collagen MeSH D12.776.860.300.250.400.537.500 – endostatins MeSH D12.776.860.300.250.400.550 – fibril-associated collagens MeSH D12.776.860.300.250.400.550.200 – Type IX collagen MeSH D12.776.860.300.250.400.550.300 – Type XII collagen MeSH D12.776.860.300.250.600 – procollagen MeSH D12.776.860.300.250.700 – tropocollagen
substantial increases in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving ... illicitly manufactured fentanyl; a concerning acceleration of the increase in drug overdose deaths, with the largest increase recorded from March 2020 to May 2020, coinciding with the implementation of widespread mitigation measures for the COVID-19 pandemic; significant increases in overdose deaths involving methamphetamine.
== Prognosis == Overall prognosis is dependent on the extent of cardiac dysfunction. Worse outcomes have been seen when echocardiography shows left ventricular wall thickness, poor systolic function and severe diastolic dysfunction. Light chain (AL-CM) Prognosis: For light-chain amyloidosis early detection leads to best possibility of therapies prolonging the period of remission. Well treated light chain cardiac amyloidosis has a 4-year survival rate of around 90%. In patients that undergo stem cell transplant the average survival time increases to 10 years. Staging systems have been developed to stratify severity of the disease, including the Mayo Biomarker Stage, which utilizes various biomarkers such as troponin I, troponin T, BNP, and NT-proBNP, and Free light chain concentrations. Familial (ATTRm-CM) Prognosis: Due to the extensive number of variables involved in this subtype, prognosis varies depending on the specific type of familial cardiac amyloidosis. Variables involve mutant vs wild type transthyretin mutation and age of onset of symptoms. In comparison to light chain amyloidosis, the familial subtype is slower to progress and has a more favorable prognosis. However, the Val 122lle mutation (most common cause of familial cardiac amyloidosis) has a 4-year survival rate of 16% with an average length of 26 months and is associated with a worse prognosis than wild type ATTR. A delay in recognition plays a major factor in this reduced survival rate.
== History == Nemonapride was developed by scientists at Yamanouchi Pharmaceuticals via structural modification of the benzamide antiemetic and gastroprokinetic agent metoclopramide. It was first described in the scientific literature by 1980. The name nemonapride was first used by 1989 and this name was designated as its INNTooltip International Nonproprietary Name in 1991. The drug was launched in May 1991. However, other sources state that it was launched in 1997.
Sources: en.wikipedia.org
== Advantages and limitations == A major advantage of ABPP is the ability to monitor the availability of the enzyme active site directly, rather than being limited to protein or mRNA abundance. Ideal ABPs would target a large, but manageable, number of enzymes (tens to hundreds) to provide researchers with a global view of the functional state of the proteome. This degree of target promiscuity must be balanced by minimal cross-reactivity with unrelated proteins. Most ABPs achieve this combination of intraclass coverage and limited extraclass reactivity by coupling appropriate reactive groups with binding elements that recognize conserved mechanistic or structural features within enzyme active sites. Furthermore, ABPP could be used to target specific proteins which were previously viewed as undruggable targets. A disadvantage of ABPs is that their design is somewhat restricted by the need to attach an electrophile or photocrosslinker, which can limit chemical diversity. Another potential drawback is that covalent modification of the active site irreversibly inhibits the target enzyme. However, in many cases it is possible to use concentrations of ABP such that only a small fraction of the active enzyme pool is labeled, minimizing perturbation of overall enzymatic activity.
7 July Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. Lewis Hamilton of Mercedes takes his ninth victory at the British Grand Prix, breaking the record for the most wins at a single circuit and Grand Prix, and the most wins at a driver's home Grand Prix, bringing an end to a 56 winless race streak and making him the first driver to win a race after their 300th Grand Prix start. 8 July The Chancellor, Rachel Reeves, announces new housebuilding targets for England, and the loosening of planning rules to encourage more new homes. The ban on onshore wind in England is lifted. 9 July Minister Jim McMahon tells BBC News that the phrase "levelling-up" will be replaced with "local government" and that his department will now be named the Ministry of Housing, Communities and Local Government. Health Secretary Wes Streeting begins talks aimed at ending a long-running pay dispute with junior doctors in England. Starmer holds his second cabinet meeting, after telling England's regional mayors he will meet with them regularly to help growth across the UK. The first meeting of the 59th Parliament of the United Kingdom takes place. Vacuum manufacturer Dyson announces it is cutting a third of its UK workforce as part of a global restructuring strategy. 10 July Starmer travels to Washington, D.C., his first foreign trip as UK Prime Minister, to attend the 75th NATO summit.
== Healthcare == UPMC Children's Hospital of Pittsburgh Community Health Partnerships, Scotland Certified Health Physicist, United States, a specialist in radiation protection and safety Centre for Health Protection, an agency of Hong Kong Cricohyoidopexy, a surgical procedure
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.